BioMarin Pharmaceuticals BMRN Net debt / EBITDA

Net debt / EBITDA at other companies

PTC TherapeuticsPTCT

-7.3×-9.8×

Zevra Therapeutics, Inc.ZVRA

-1.6×—

XER

Xeris Biopharma Holdings, Inc.XERS

4.4×—

Opko HealthOPK

1.2×—

Krystal Biotech, Inc.KRYS

-2.7×+0.1×

FAQ

What is BioMarin Pharmaceuticals's net debt / EBITDA?

BioMarin Pharmaceuticals (BMRN) reported net debt / EBITDA of 9.5× in Q2 2026.

How has BioMarin Pharmaceuticals's net debt / EBITDA changed year-over-year?

BioMarin Pharmaceuticals's net debt / EBITDA increased by 1426.3% year-over-year, from -0.7× to 9.5×.

What is the long-term trend for BioMarin Pharmaceuticals's net debt / EBITDA?

Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's net debt / EBITDA has grown at a -33.5% compound annual growth rate (CAGR), from -9.6× to -1.2×.

What does net debt / EBITDA mean?

Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.